Loading…
Loading…
NASHVILLE, Tenn., July 07, 2026 (GLOBE NEWSWIRE) -- Healthcare Realty Trust Incorporated (NYSE:HR) today announced that on Thursday, July 30, 2026, after the market closes, it is scheduled to report results for the second quarter of 2026.
enGene Therapeutics Inc. (Nasdaq: ENGN, âenGeneâ or the âCompanyâ), a clinical-stage, non-viral genetic medicines company today announced its financial
EXPD, VNCE, UCTT, PRG and TNET have been added to the Zacks Rank #1 (Strong Buy) List on June 8, 2026.
Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor â palbociclib
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and spons
[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYXÂ
Healthcare Realty Trust is well positioned in the outpatient medical REIT space, benefiting from macro trends like aging demographics and rising outpatient care demand. HR's growth is supported by a nationwide portfolio, strong tenant retention, and opportunities for property acquisitions and lease growth. Balance sheet risk is mitigated by competitive debt metrics and diversified asset exposure.
AstraZeneca and Daiichi Sankyo's ENHERTUÂ (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadj
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for HR and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.